Literature DB >> 31931042

Estrogen protects neuroblastoma cell from amyloid-β 42 (Aβ42)-induced apoptosis via TXNIP/TRX axis and AMPK signaling.

Qiong Pan1, Ke Guo2, Min Xue1, Qiuyun Tu3.   

Abstract

Alzheimer's disease (AD), a massive challenge to global health, is featured with the extracellular plaques made up of amyloid-β 42 (Aβ42) and the intracellular neurofibrillary pathology composed of the microtubule-associated protein tau. Women seem to have a higher vulnerability to AD. In the present study, we identified Thioredoxin-interacting protein (TXNIP) as a specifically highly-expressed gene in the hippocampus in female AD patients by bioinformatics analysis. Consistently, in the hippocampus in female AD mice, apoptosis and TXNIP expression were enhanced while TRX expression was suppressed. In Aβ42-stimulated SH-SY5Y cells, the administration of estradiol significantly rescued Aβ42-suppressed cell viability and protein level of TRX while inhibited Aβ42-induced increases in ROS production, cell apoptosis, ΔΨm, and the protein levels of PERK, IREα, and TXNIP, further confirming the potential role of estrogen in AD progression and the involvement of TXNIP/TRX axis. Furthermore, the protective effects of estradiol against Aβ42-induced in vitro neurotoxicity on SH-SY5Y cells could be significantly reversed by AMPK inhibitor, Compound C, indicating that estradiol could improve Aβ42-induced AD via TXNIP/TRX and AMPK signaling. In summary, we demonstrated the cellular function of estradiol on Aβ42-induced in vitro neurotoxicity on SH-SY5Y cells and a novel mechanism of TXNIP/TRX axis involved in estradiol function via AMPK signaling.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AMPK signaling; Alzheimer's disease (AD); Amyloid-β 42 (Aβ42); Estradiol; Neurotoxicity; Thioredoxin-interacting protein (TXNIP)

Mesh:

Substances:

Year:  2020        PMID: 31931042     DOI: 10.1016/j.neuint.2020.104685

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  8 in total

1.  miR-223 Enhances the Neuroprotection of Estradiol Against Oxidative Stress Injury by Inhibiting the FOXO3/TXNIP Axis.

Authors:  Qiong Pan; Jiezhi Ma; Ke Guo
Journal:  Neurochem Res       Date:  2021-11-29       Impact factor: 3.996

2.  TXNIP Links Anticipatory Unfolded Protein Response to Estrogen Reprogramming Glucose Metabolism in Breast Cancer Cells.

Authors:  Yuanzhong Wang; Shiuan Chen
Journal:  Endocrinology       Date:  2022-01-01       Impact factor: 5.051

Review 3.  α-Arrestins and Their Functions: From Yeast to Human Health.

Authors:  Kacper Zbieralski; Donata Wawrzycka
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

Review 4.  The Potential Roles of Redox Enzymes in Alzheimer's Disease: Focus on Thioredoxin.

Authors:  Jinjing Jia; Xiansi Zeng; Guangtao Xu; Zhanqi Wang
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 4.146

Review 5.  Thioredoxin-Interacting Protein (TXNIP) with Focus on Brain and Neurodegenerative Diseases.

Authors:  Haruka Tsubaki; Ikuo Tooyama; Douglas Gordon Walker
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

Review 6.  Thioredoxin-interacting protein (TXNIP) as a target for Alzheimer's disease: flavonoids and phenols.

Authors:  Meng Zhang; Guanhua Hu; Nan Shao; Yunpeng Qin; Qian Chen; Yan Wang; Peng Zhou; Biao Cai
Journal:  Inflammopharmacology       Date:  2021-08-04       Impact factor: 4.473

Review 7.  Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook.

Authors:  Naila Qayyum; Muhammad Haseeb; Moon Suk Kim; Sangdun Choi
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

Review 8.  Research Progress of TXNIP as a Tumor Suppressor Gene Participating in the Metabolic Reprogramming and Oxidative Stress of Cancer Cells in Various Cancers.

Authors:  Yiting Chen; Jieling Ning; Wenjie Cao; Shuanglian Wang; Tao Du; Jiahui Jiang; Xueping Feng; Bin Zhang
Journal:  Front Oncol       Date:  2020-10-21       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.